Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 5

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 5
---
s from sale of common stock, Related party 
     3,000,000  
     - 
  
    Proceeds from sale of common stock 
     5,550,008  
     5,832,973 
  
    Net cash flows provided by financing activities 
     8,550,008  
     5,298,027 

    Net change in cash 
     6,063,167  
     833,407 
  
    Cash, beginning of period 
     1,266,131  
     1,231 
  
    Cash, end of period 
    $7,329,298  
    $834,638 

    Supplemental schedule of non-cash financing activities: 

    Cash paid for interest 
    $-  
    $- 
  
    Cash paid for taxes 
    $-  
    $- 

See
notes to condensed unaudited financial statements

6

TELOMIR
PHARMACEUTICALS, INC.

NOTES
TO CONDENSED FINANCIAL STATEMENTS

September
30, 2025

(Unaudited)

Note
1. Description of business and summary of significant accounting policies:

Telomir
Pharmaceuticals (NASDAQ:TELO) is a pre-clinical stage biotechnology company developing therapies designed to target the root epigenetic
mechanisms underlying cancer, aging, and degenerative disease. The Company’s lead candidate, Telomir-1, has demonstrated activity
in preclinical studies involving modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression,
cellular function, and genomic stability. Telomir-1 is a novel oral small molecule metal ion regulator designed to extend telomere caps,
maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal
ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder
that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and Age-related
Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease.

Basis
of presentation

The
accompanying unaudited condensed financial statements include the accounts of the Company and have been prepared in accordance with accounting